Navigation Links
Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Date:9/19/2008

that prevent cell-to-cell transmission of virus down the respiratory tract, potentially reducing the severity of influenza disease; and cell mediated immune responses to M1 may lead to destruction of cells already infected. Further, the vaccine is made in cell culture rather than eggs, which permits an exact genetic match to the flu strains causing illness since there is no requirement for adapting the vaccine to grow in eggs.

"We are pleased to complete enrollment so quickly of our seasonal influenza vaccine Phase IIa trial", said Dr. Rahul Singhvi, President and CEO of Novavax. "The completion of enrollment for this critical clinical trial within a week of its initiation should enable us to release top line data from this study in the fourth quarter of this year. I congratulate our team on this accomplishment and for advancing two novel influenza vaccines into Phase II development this year."

Novavax's novel manufacturing approach

Novavax's manufacturing process makes it possible to rapidly produce a vaccine that contains strains that are an exact genetic match to the strains circulating in the community causing influenza disease. Novavax's influenza VLPs are produced through recombinant technology in insect cell culture, utilizing a manufacturing process that will consist entirely of disposable, ready-to-use equipment. Current yields are 7 to 10 times higher than those of traditional egg-based or mammalian cell culture manufacturing. Because the Novavax process involves recombinant technology and does not require a live influenza virus, a matched vaccine for the first seasonal influenza clinical trial was manufactured within 12 weeks of identification of the Centers for Disease Control and Prevention ("CDC") released seasonal strains, or approximately half the time required to manufacture egg-based vaccines. The ability to rapidly respond to the identification of annual seasonal strains may be important in providing timely vaccine in advance
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Closing of $18 Million Registered Direct Offering
3. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
4. Novavax to Join Russell 3000 Index
5. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
6. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
7. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
8. Novavax Reports First Quarter 2008 Financial Results
9. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
10. Novavax Opens Its First U.S. Vaccine Plant
11. Novavax CEO to Present at the World Vaccine Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014   MSC , a healthcare ... today announced the appointment of Mary Beth Loesch ... 28 years of experience preparing companies for rapid growth ... Executive Vice President of Corporate Development and Healthcare. In ... business , as well as corporate strategy and marketing. ...
(Date:8/27/2014)... of nature,s mysteries is how plants survive impact ... the sun,s rays, while using this energy for ... in the plant,s blades quickly dissipate the energy ... quakes. Researchers at DTU Physics have now managed ... algae and bacteria contain light-absorbing proteins which play ...
(Date:8/27/2014)... The Global and China Trifluoroacetic Acid ... current state of the Trifluoroacetic Acid industry in Global ... of the industry, including definitions, applications and industry chain ... are provided with a focus on history, developments, trends ... the international and Chinese situation is also offered. , ...
(Date:8/27/2014)... 27, 2014 Reportlinker.com announces that a ... catalogue: Global Chelating Agents Market 2014-2018 ... About Chelating Agent A chelating agent is a ... metal ions, thereby forming a metal-ion complex. It ... on chemical processes, formulations, and the environment by ...
Breaking Biology Technology:MSC names Mary Beth Loesch President and CEO 2DTU researchers film protein quake for the first time 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4
... Signum Biosciences, Inc. today announced the appointment of Dr. Braham Shroot ... replaces Dr. Gregory Stock who will continue to remain active ... , , ... to Signum an outstanding track record of success in growing value at ...
... to conduct the study at the Norris Comprehensive Cancer Center of ... , , ... - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ... endocrine therapy, today announced that the National Institutes of Health ("NIH") has ...
... Aug. 4 Forte, LLC, today announced ... probate database and estate recovery application that significantly ... OnDemand provides access to a proprietary database of ... matching algorithms that accurately match deceased accounts to ...
Cached Biology Technology:Signum Biosciences Names Braham Shroot as Chief Executive Officer 2Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 2Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 3Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 4Forte Launches Probate Finder OnDemandâ„¢ 2Forte Launches Probate Finder OnDemandâ„¢ 3
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new ... Law Enforcement Biometrics Market in North ... About Biometrics Biometrics is a technology ... of their physical or behavioral patterns. It involves ... such as fingerprints, face recognition, DNA, palm print, ...
(Date:8/27/2014)... N.C. -- Duke University researchers have identified a gene ... called OSCA1, encodes a protein in the cell membrane ... adjusts the plant,s water conservation machinery accordingly. , ... associate professor of biology at Duke. , The ... Nature , could make it easier to feed the ...
(Date:8/27/2014)... ago a group of fish began exploring land and evolved ... just how these ancient fish used their fishy bodies and ... at play remain scientific mysteries. , Researchers at McGill ... a living fish, called Polypterus , to help show ... out of the water. Polypterus is an African ...
Breaking Biology News(10 mins):Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5Water 'thermostat' could help engineer drought-resistant crops 2Walking fish reveal how our ancestors evolved onto land 2
... are urgently needed in resource-limited countries. A ... Microbiology colloquium, "Bringing the Lab to the Patient: ... the challenges inherent in bringing new medical devices ... where they are needed most. Point-of-care diagnostics (POCTs) ...
... helped open a new door of possibility in the high-stakes ... an international team, the scientists including Stanford Woods Institute ... found a way to create future ocean conditions in a ... the device can mimic the composition of the future ocean ...
... world dolomite is quite common. More than 90 percent of ... first described scientifically in the 18th century. But who would ... not fully understood, although geologists are aware of large deposits ... years. The process of recent primary dolomite formation is restricted ...
Cached Biology News:Report addresses challenges in implementing new diagnostic tests where they are needed most 2Stanford researchers help predict the oceans of the future with a mini-lab 2How does dolomite form? 2
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
... to Yersinia pestis This antibody ... . Immunogen: Purified ... vaccine strain EV76. ... F1 capsular antigen. There is no ...
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
Biology Products: